Patents

Novartis slashes 1,960 US sales and marketing jobs amid hypertension franchise implosion

January 13, 2012

Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.
 

Pfizer's post-expiry plan for Lipitor: maximize brand's sales

November 02, 2011

Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.
 

Brilinta boosts AstraZeneca, but can it carry them over the cliff?

July 21, 2011

The FDA gave the green light to AstraZeneca's Brilinta (ticagrelor) anti-platelet for heart attack prevention, but the brand will carry a black box warning, a Risk Evaluation and Mitigation Strategy requirement and an obligation to educate doctors about possible risks of use in users of high-dose aspirin.
 

Pfizer sales up, as it braces for Lipitor down side

February 01, 2011

Pfizer reported higher fourth-quarter sales, but the world's largest drug maker also revealed more downsizing and R&D cuts as it braces for the expiry of the Lipitor patent later this year.
 

Company news: Takeda and Teva

December 28, 2010

Takeda granted generics firm Teva a license to market authorized copies in the US, starting Aug. 17, 2012, for best-selling diabetes pill Actos, and on Dec. 14, 2012, for Actoplus met (Actos plus metformin).
 

King Pharma resubmits abuse-resistant oxycodone to FDA

December 28, 2010

Two years after receiving a Complete Response letter from FDA about Remoxy, King Pharmaceuticals and Pain Therapeutics announced that they had resubmitted the drug for approval yesterday. A thumbs up or thumbs down from FDA is expected in June.
 

Ruling in FTC-Watson case may sway pay-for-delay debate in Senate

July 19, 2010

A US magistrate judge ruled that the Federal Trade Commission overstepped its authority when the agency tried to pressure a generic drug company to enter into a business deal with a competitor.
 

Watson: FTC abused power in trying to 'engineer' entry of generic Provigil

May 27, 2010

The FTC, which opposes reverse-payment patent settlements but has failed to muffle them via the courts or healthcare reform legislation, is now trying some new tactics: harassment, use of privileged information and attempting to force a pharma company to partner with another firm against its will.
 

No sure fixes for pharma's patent cliff

May 07, 2010

With a spate of high-margin blockbusters going off patent and a lack of replacement products, a Bernstein Research conference explored three potential solutions to the patent cliff.
 

Global drug sales to grow 5%-8% through 2014 despite patent losses, says IMS

April 20, 2010

Global sales of pharmaceuticals will grow at a rate of 5%-8% annually over the next five years, IMS Health forecasts -- even as products with sales of more than $142 billion lose patent protection in top markets, reducing drug spending by $80-$100 billion.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!
 
Popular Topics
Adherence Advertising Approval Brand Corporate Reputation DDMAC Digital Direct To Consumer (DTC) DTC Facebook FDA Generic Guidance Launch Loyalty Program Magazine Major Statement Manufacturing Media Medical Education Off-label Online OPDP Social Media Television